GILD
Gilead Sciences, Inc. · Healthcare · Drug Manufacturers - General
Señales de momentum (gestores comparables):
amplitud de titulares -4.3% ·
flujo de acciones +2.0% ·
nuevas posiciones netas -4.5%
— fórmula
Acumulación concentrada — aumento de acciones entre menos titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 175 | +1 | 941.63M | $119.04B | +5 | −3 |
| Q1 2026 | 176 | +4 | 930.86M | $129.53B | +6 | −3 |
| Q4 2025 | 171 | 0 | 1.00B | $122.89B | +1 | — |
| Q3 2025 | 23 | -1 | 603.99M | $67.03B | — | −2 |
| Q2 2025 | 22 | -1 | 560.26M | $62.11B | — | −1 |
| Q1 2025 | 20 | 0 | 255.31M | $28.60B | — | — |
| Q4 2024 | 20 | +1 | 270.33M | $24.97B | +1 | — |
| Q3 2024 | 18 | 0 | 213.42M | $17.89B | — | — |
| Q2 2024 | 18 | — | 202.41M | $13.88B | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (pasivo) | 119.36M | — | $13.23B | 0.2% | n/c | 1 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (pasivo) | 114.88M | — | $12.74B | 0.2% | n/c | 1 | SEC ↗ ×24 |
| 3 | Fidelity (FMR) ✦ | 59.96M | — | $6.65B | 0.4% | n/c | 1 | SEC ↗ ×8 |
| 4 | State Street Global Advisors ✦ (pasivo) | 59.19M | -0.6% | $6.56B | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 5 | Capital World Investors ✦ | 46.30M | -13.5% | $5.13B | 0.7% | ▼ Trim | 5 | SEC ↗ |
| 6 | Wellington Management ✦ | 37.53M | +37.2% | $4.16B | 0.8% | ▲ Add | 5 | SEC ↗ ×9 |
| 7 | Dodge & Cox ✦ | 30.82M | -5.7% | $3.42B | 1.9% | ▼ Trim | 5 | SEC ↗ |
| 8 | Geode Capital Management ✦ (pasivo) | 29.21M | +2.5% | $3.23B | 0.2% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | T. Rowe Price ✦ | 23.59M | +60.4% | $2.62B | 0.3% | ▲ Add | 5 | SEC ↗ ×2 |
| 10 | Norges Bank ✦ (pasivo) | 19.39M | -2.3% | $2.15B | 0.3% | ▼ Trim | 5 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 5.67M | +4.0% | $628.23M | 0.8% | ▲ Add | 5 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 5.47M | +1.8% | $606.52M | 0.5% | ▲ Add | 5 | SEC ↗ ×2 |
| 13 | AQR Capital Management ✦ | 2.47M | +32.5% | $272.21M | 0.2% | ▲ Add | 5 | SEC ↗ ×7 |
| 14 | Marshall Wace ✦ | 1.95M | +152.1% | $216.29M | 0.3% | ▲ Add | 5 | SEC ↗ ×2 |
| 15 | Adage Capital Partners ✦ | 1.45M | +10.1% | $161.12M | 0.3% | ▲ Add | 3 | SEC ↗ |
| 16 | Millennium Management ✦ | 764.15K | -69.9% | $84.72M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 700.23K | +54.3% | $77.63M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 18 | Bridgewater Associates ✦ | 666.30K | +32.5% | $73.87M | 0.3% | ▲ Add | 5 | SEC ↗ |
| 19 | Arrowstreet Capital ✦ | 426.58K | +690.1% | $47.30M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 282.20K | +12.4% | $31.29M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 21 | Point72 Asset Management ✦ | 164.73K | -67.8% | $18.26M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 22 | Fisher Asset Management ✦ | 10.70K | +54.0% | $1.19M | 0.0% | ▲ Add | 5 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Two Sigma Investments | $4.86M | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1 tenedores, 61.30K acciones, $8,543 declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 1.60K acc. · $229,907
Officer · 600 acc. · $87,174
Officer · 800 acc. · $115,566
Officer · 3.00K acc. · $435,870
Officer, Director · 7.99K acc. · $1.19M
Officer, Director · 1.60K acc. · $236,014
Officer, Director · 5.41K acc. · $807,856
Director · 3.40K acc. · $504,296
Director · 3.12K acc. · $462,432
Director · 4.60K acc. · $684,590
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología